Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
arcticnovartis
- NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1
- Data showed consistent improvements across secondary outcome measures, and a favorable safety profile1
- Novartis plans to submit to health authorities globally in early 2026
- If approved, ianalumab could become first targeted treatment for this heterogeneous, systemic autoimmune disease
